Compare Wipro Limited (WIT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wipro Limited vs State Street SPDR S&P Biotech ETF — how do they compare? Wipro Limited trades at $1.71 (market cap $16.22B), while State Street SPDR S&P Biotech ETF trades at $153.61 (market cap $10.11B). The key difference: Wipro Limited is the larger of the two by market cap, and Wipro Limited pays a 5.19% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wipro Limited for 41 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| WIT | XBI | |
|---|---|---|
Market Cap | $16.22B | $10.11B |
Volume | 9,028,667 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $3.06 | $169.55 |
52-Week Low | $1.61 | $104.99 |
Typical Hold Time | 41 Days | 37 Days |
Enterprise Value | $14.33B | — |
Dividend Yield | 5.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WIT trades at $1.67, down 0.6% on the day, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company reported revenue of $890.88 billion in 2025 with a net income margin of 13.92%, though recent quarters have seen earnings misses against expectations. Recent news highlights Wipro's AI initiatives boosting productivity and new cybersecurity partnerships.
The outlook is mixed; valuation ratios like a P/E of 12.78 appear reasonable, but analyst consensus is cautious with only 19% buy ratings. Key risks include competitive pressures and macroeconomic uncertainty affecting tech spending. Upside hinges on execution of AI strategies and reversing earnings misses.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
